## AMENDMENTS TO THE CLAIMS

1.    **(Currently Amended)**  A process of preparing cells for cell therapy, comprising the steps of:

    inducing helper T ~~Th~~ cells that have a nonspecific antitumor activity; and

    imparting antigen specificity to the helper T ~~Th~~ cells

wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.

2.    **(Cancelled)**

3.    **(Currently Amended)**  The process for preparing cells for cell therapy according to claim 1, wherein the step of imparting antigen specificity to the helper T ~~Th~~ cells is carried out by transducing a gene for a class I-restricted T cell receptor gene ~~TCR~~ that recognizes a cancer-associated antigen.

4.    **(Currently Amended)**  The process for preparing cells for cell therapy according to claim 1, wherein the step of imparting antigen specificity to the helper T ~~Th~~ cells is carried out by transducing a gene for a class II-restricted T cell receptor gene ~~TCR~~ that recognizes a cancer-associated antigen.

5.    **(Currently Amended)**  The process for preparing cells for cell therapy according to any of claims 1, 3 or 4 ~~2 to 4~~, wherein the cancer-associated antigen is selected from the group consisting of Wilms' Tumor 1 ~~WT1~~, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1, MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.

6.    **(Withdrawn-Currently Amended)**  The process for preparing cells for cell therapy according to claim 1, wherein the step of inducing helper T ~~Th~~ cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody and IL-2.

7.    **(Currently Amended)**  The process for preparing cells for cell therapy according to any of claims 1, 3, 4 or 6 ~~1 to 6~~, further comprising a step of purifying the helper T ~~Th~~ cells to which antigen specificity has been imparted.

8.    **(Currently Amended)**  The process for preparing cells for cell therapy according to claim 7, wherein the step of purifying the helper T ~~Th~~ cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.

9.    **(Currently Amended)**  A process of preparing cells for cell therapy, comprising the steps of:

inducing <u>helper T 1</u> <s>Th1</s> cells and <u>cytotoxic T 1</u> <s>Tc1</s> cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the <u>helper T 1</u> <s>Th1</s> cells and <u>cytotoxic T 1</u> <s>Tc1</s> cells <u>wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.</u>

10.    **(Cancelled)**

11.    **(Currently Amended)**  The process for preparing cells for cell therapy according to claim 9, wherein the step of imparting antigen specificity to the <u>helper T 1</u> <s>Th1</s> cells and <u>cytotoxic T 1</u> <s>Tc1</s> cells is carried out by transducing <s>a gene for</s> a class I-restricted <u>T cell receptor gene</u> <s>TCR</s> that recognizes a cancer-associated antigen.

12.    **(Currently Amended)**  The process for preparing cells for cell therapy according to claim 9, wherein the step of imparting antigen specificity to the <u>helper T 1</u> <s>Th1</s> cells and <u>cytotoxic T 1</u> <s>Tc1</s> cells is carried out by transducing <s>a  gene  for</s> a class II-restricted <u>T cell receptor gene</u> <s>TCR</s> that recognizes a cancer-associated antigen.

13.    **(Currently Amended)**  The process for preparing cells for cell therapy according to any of claims <s>9 to 12</s> <u>9, 11 or 12</u>, wherein the cancer-associated antigen is selected from the group consisting of <u>Wilms' Tumor 1</u> <s>WT1</s>, CEA, AFP, CA19-9, CA125, PSA, CA72-4, SCC, MK-1,

MUC-1, p53, HER2, G250, gp-100, MAGE, BAGE, SART, MART, MYCN, BCR-ABL, TRP, LAGE, GAGE, and NY-ESO1.


14.    **(Withdrawn-Currently Amended)**   The process for preparing cells for cell therapy according to claim 9, wherein the step of inducing helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells having a nonspecific antitumor activity is carried out by culturing a T cell-containing material in the presence of anti-CD3 antibody, IL-2, and IL-12.


15.    **(Currently Amended)** The process for preparing cells for cell therapy according to any of claims 9, 11, 12 or 14 ~~9 to 14~~, further comprising a step of separating the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells to which antigen specificity has been imparted.


16.    **(Currently Amended)**   The process for preparing cells for cell therapy according to claim 15, wherein the process of separating the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells to which antigen specificity has been imparted is carried out by using antibody-bearing magnetic beads.


17.    **(Currently Amended)**   The process for preparing cells for cell therapy according to claim 15 ~~or 16~~, further comprising a step of mixing the separated helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells in any given proportion.


GMM/LTP/bsh

18.    **(Withdrawn-Currently Amended)**   Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper T ~~Th~~ cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T ~~Th~~ cells, wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.


19.    **(Withdrawn-Currently Amended)**   Cells for cell therapy, that are produced by a process comprising the steps of:

inducing helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells that have a nonspecific antitumor activity; and

imparting antigen specificity to the helper T 1 ~~Th1~~ cells and cytotoxic T 1 ~~Tc1~~ cells, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen.


20.    **(Withdrawn-Currently Amended)**   A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes helper T ~~Th~~ cells that have a nonspecific antitumor activity;

imparting antigen specificity to the helper T ~~Th~~ cells, wherein the step of imparting antigen specificity to the helper T cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen; and

GMM/LTP/bsh

administering to the patient the <u>helper T</u> T̶h̶ cells to which antigen specificity has been imparted.


21.     **(Withdrawn-Currently Amended)**     A method for preventing or treating tumor, comprising the steps of:

isolating leukocytes from a patient;

inducing from the leukocytes <u>helper T 1</u> T̶h̶1̶ cells and <u>cytotoxic T 1</u> T̶c̶1̶ cells that have a nonspecific antitumor activity;

imparting antigen specificity to the <u>helper T 1</u> T̶h̶1̶ cells and <u>cytotoxic T 1</u> T̶c̶1̶ cells<u>, wherein the step of imparting antigen specificity to the helper T 1 cells and cytotoxic T 1 cells is carried out by transducing a T cell receptor gene that recognizes a cancer-associated antigen</u>; and

administering to the patient the <u>helper T 1</u> T̶h̶1̶ cells and <u>cytotoxic T 1</u> T̶c̶1̶ cells to which antigen specificity has been imparted.

GMM/LTP/bsh